CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

NCT06081478 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia
B-cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: CD19/CD22-bispecific CAR-T cells

Sponsor

Beijing Tongren Hospital